A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer. This is an ASCO Meeting ...
Optimizing an NGS low-pass–based method to detect genomic instability as a PARP inhibitor predictive biomarker in high-grade serous ovarian cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results